

Title (en)

ORAL ADMINISTRATION OF CHICKEN YOLK ANTIBODIES TO TREAT DISEASE

Title (de)

ORALE VERABREICHUNG VON ANTIKOERPERN AUS HUEHNEREIGELB ZUR BEHANDLUNG VON KRANKHEITEN

Title (fr)

ADMINISTRATION ORALE D'ANTICORPS A BASE DE JAUNE D'OEUF DE POULE POUR LE TRAITEMENT DE MALADIES

Publication

EP 0930891 A1 19990728 (EN)

Application

EP 97909921 A 19971002

Priority

- US 9717722 W 19971002
- US 72440896 A 19961002

Abstract (en)

[origin: WO9814209A1] Broadly, the present invention is directed to the use of egg antibody preparations in the treatment of systemic disease in human and non-human mammals. IgY antibodies are first obtained from the egg of a domestic fowl hen which has been actively immunized against said one or more pathogenic organisms by injection with an immunogen containing immunogenic determinants specific to elicit such antibodies. The antibodies are then administered orally to a mammal suffering from an infectious systemic disease caused or exacerbated by such pathogenic organism or organisms. This invention, thus, is capable of providing passive immunity to patients with failing immunity or that are immunologically naive. It is unnecessary to separate the antibodies from the egg yolk, so processing and administration are convenient and inexpensive. Antibody produced from egg yolks of hens immunized against specific antigens are effective in controlling noxious agents, whether viral, bacterial, fungal, protozoal, toxins, enzymes, inflammatory mediators, prostaglandins, leukotrienes, thromboxines and other messenger molecules, sarcomas or carcinomas, not only within the bowel but also in tissues remote thereto. The immunogenic determinant may comprise only a specific portion of the pathogenic organism, e.g., the loop or coat of a virus or the fimbria of a piliated bacterium. The method of this invention has been shown to be efficacious in the treatment of AIDS in human beings, TNF mediated septic shock in mice, and in lowering somatic cell count in dairy cattle.

IPC 1-7

A61K 39/00; **A61K 39/395**; **A61K 39/40**; **A61K 39/42**; **A61K 39/44**; **C07K 16/00**; **C07K 16/02**; **C07K 16/08**; **C07K 16/12**; **C07K 16/30**

IPC 8 full level

A61K 39/00 (2006.01); **A61K 39/395** (2006.01); **A61P 9/00** (2006.01); **A61P 13/12** (2006.01); **A61P 25/00** (2006.01); **A61P 29/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/18** (2006.01); **A61P 31/20** (2006.01); **A61P 31/22** (2006.01); **A61P 33/02** (2006.01); **A61P 35/00** (2006.01); **C07K 16/02** (2006.01); **C07K 16/24** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP KR)

A61K 39/00 (2013.01 - KR); **A61P 9/00** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 31/20** (2017.12 - EP); **A61P 31/22** (2017.12 - EP); **A61P 33/02** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **C07K 16/02** (2013.01 - EP); **C07K 16/241** (2013.01 - EP); **A61K 38/00** (2013.01 - EP)

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9814209 A1 19980409; AU 4741997 A 19980424; AU 729502 B2 20010201; CA 2267421 A1 19980409; EP 0930891 A1 19990728; EP 0930891 A4 20010704; JP 2001501622 A 20010206; KR 20000048855 A 20000725; NZ 335170 A 20010831

DOCDB simple family (application)

US 9717722 W 19971002; AU 4741997 A 19971002; CA 2267421 A 19971002; EP 97909921 A 19971002; JP 51684798 A 19971002; KR 19997002857 A 19990402; NZ 33517097 A 19971002